ZYBT — Zhengye Biotechnology Holding Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1975641 ·
China
Last close
$1.30
Market Cap
$61.85M
52W High
$8.01
52W Low
$0.62
ADV30
114,600
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 436,472,000 | 50,332,000 | 129,757,000 |
| Jun 2025 | — | — | — | — | 504,628,000 | 45,607,000 | 139,535,000 |
| Dec 2024 | — | — | — | — | 493,247,000 | 18,604,000 | 140,707,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-21,633,000
Inventory
$39,166,000
Receivables
$18,485,000
ST Investments
$1,560,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$116,362,000
EBITDA
$-44,623,000
Free Cash Flow
$39,576,752
Enterprise Value
$153,514,640
Total Cash
$51,892,000
Total Debt
$75,083,000
Shares Out
47,391,376
Trailing EPS
$-0.22
Book Value
$0.78
ROE
-25.2%
ROA
-9.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 116,362,000 | -68,254,000 | -69,784,000 | 436,472,000 | 129,757,000 | 249,848,000 | 13,333,000 |
| Dec 2024 | 186,356,000 | 17,172,000 | 11,311,000 | 493,247,000 | 140,707,000 | 283,959,000 | 41,046,000 |
| Dec 2023 | 211,651,000 | 47,639,000 | 31,457,000 | 499,888,000 | 160,616,000 | 272,850,000 | 48,184,000 |
| Dec 2022 | 260,269,000 | 66,089,000 | 46,735,000 | 519,674,000 | 162,807,000 | 296,497,000 | 17,335,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TLPH | TALPHERA, INC. | $61.25M | $1.18 | — |
| HYPD | HYPERION DEFI, INC. | $62.78M | $4.04 | — |
| BOLD | Boundless Bio, Inc. | $60.51M | $2.66 | — |
| XLO | Xilio Therapeutics, Inc. | $59.48M | $9.04 | — |
| RNTX | Rein Therapeutics, Inc. | $64.53M | $0.75 | — |
News headlines (Yahoo Finance, 1h cache)
Zhengye Biotechnology Says No Material Events Behind Unusual Trading Activity (NASDAQ:ZYBT)
2026-07-21 14:34 · Yahoo
Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
2026-06-04 20:05 · Yahoo
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure
2026-04-06 13:25 · Yahoo
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
2026-07-21 12:30 · Yahoo
Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement
2026-08-06 12:00 · Yahoo
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results
2026-04-28 20:30 · Yahoo
Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders
2026-02-10 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.